Cynomolgus / Rhesus macaque B7-2 / CD86 Protein, Fc Tag

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation) . CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

This protein carries a human IgG1 Fc tag at the C-terminus. The protein has a calculated MW of 52 kDa. The protein migrates as 76-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Immobilized Cynomolgus / Rhesus macaque CTLA-4, His Tag (Cat. No. CT4-C5227) at 2 μg/mL (100 μL/well) can bind Cynomolgus / Rhesus macaque B7-2, Fc Tag (Cat. No. CD6-C5254) with a linear range of 0.039-1.25 μg/mL (QC tested).